David Kateb, MD
Pulmonary Disease · Delray Beach, FLNPI 1679677611
Payments from drug & device makers
Across 641 payments — averaging $51.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi US Services Inc.$11K
- AstraZeneca$6K
- Boehringer Ingelheim$5K
- GSK$3K
- Mallinckrodt Hospital Products Inc.$2K
- ANI Pharmaceuticals, Inc.$919
- plus $5K from 31 others
What the payments were for
- Consulting fees$1171%
- Speaking & faculty fees$1,5157%
- Food & beverage$19,84490%
- Education$3892%
- Gifts$2401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi US Services Inc. | 1 | $11,184 |
| AstraZeneca | 177 | $5,797 |
| Boehringer Ingelheim | 108 | $4,874 |
| GSK | 110 | $3,423 |
| Mallinckrodt Hospital Products Inc. | 51 | $1,668 |
| ANI Pharmaceuticals, Inc. | 44 | $919 |
| Novo Nordisk | 11 | $903 |
| Mallinckrodt Enterprises LLC | 11 | $509 |
| Sanofi | 11 | $489 |
| United Therapeutics Corporation | 10 | $395 |
| Regeneron Healthcare Solutions, Inc. | 14 | $393 |
| Mylan Specialty L.p. | 13 | $314 |
| Esperion Therapeutics, Inc. | 2 | $250 |
| Atricure, Inc. | 2 | $248 |
| Resmed Corp | 1 | $240 |
| Insmed, Inc. | 13 | $230 |
| Johnson & Johnson | 8 | $226 |
| Philips North America LLC | 10 | $159 |
| Sunovion Pharmaceuticals Inc. | 10 | $155 |
| E.r. Squibb & Sons, L.L.C. | 2 | $139 |
| Abbott | 2 | $128 |
| Grifols USA, LLC | 7 | $120 |
| Medline Industries LP | 1 | $86 |
| Exact Sciences | 3 | $65 |
| Pfizer | 3 | $49 |
| Arbor Pharmaceuticals, Inc. | 3 | $43 |
| Medtronic | 1 | $43 |
| Electromed, Inc. | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Merck | 1 | $26 |
| Corcept Therapeutics | 1 | $24 |
| Fisher & Paykel Healthcare Inc | 1 | $23 |
| TMS Neurohealth Centers Inc. | 1 | $20 |
| Amgen | 1 | $19 |
| Circassia Inc. | 1 | $18 |
| Baxter Healthcare | 1 | $17 |
| Lilly USA, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$33,289 in reported general payments places this provider in the 80th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CortrophinCorticotropin | 11 | $757,536 |
| ActharCorticotropin | 14 | $734,533 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 468 | $351,866 |
| OfevNintedanib Esylate | 25 | $326,322 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 285 | $235,617 |
| OzempicSemaglutide | 77 | $76,769 |
| EliquisApixaban | 66 | $49,172 |
| SymbicortBudesonide/Formoterol Fumarate | 149 | $44,298 |
| Breo ElliptaFluticasone/Vilanterol | 78 | $43,267 |
| Spiriva RespimatTiotropium Bromide | 50 | $34,369 |
| RybelsusSemaglutide | 11 | $19,086 |
| FarxigaDapagliflozin Propanediol | 17 | $17,171 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 117 | $16,442 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 25 | $15,594 |
| JanuviaSitagliptin Phosphate | 11 | $10,861 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mallinckrodt Hospital Products Inc.Acthar | $1,668 | $734,53314 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $3,423 | $413,334582 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $4,874 | $366,76886 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Farxiga, Bevespi Aerosphere | $5,797 | $302,142463 claims |
| Novo NordiskOzempic, Rybelsus | $903 | $95,85688 claims |
| PfizerEliquis | $49 | $49,17266 claims |
| MerckJanuvia | $26 | $10,86111 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $919 | $49040 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Delray Beach
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
- Carlos MartinezHomestead$9.2M
- Leonard DunnDunedin$7.6M
- Francis AverillClearwater$6.3M
- Charles BurgerJacksonville$5.6M
- Daniel LorchBrandon$5.5M
- Lourdes BoschMiami$4.2M
- Raj KarunakaraOcala$4M
- Neal WarshoffLoxahatchee$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.